Mission Statement, Vision, & Core Values (2026) of Sinocare Inc.

Founded in 2002, Sinocare Inc. (300298.SZ) has grown into a global leader in digital diabetes management, offering blood glucose meters, CGM systems and digital health solutions that reach patients in 135 countries; its mission to provide innovative, high-quality care "guided by love" underpins a vision to be "The Leading Diabetes Digital Management Expert in the World," while its core values-customer focus, employee care, partner collaboration, societal responsibility and shareholder respect-drive product accessibility and ethical practice; the company's heavy investment in innovation, including > 200 million CNY in R&D in 2021, combined with international quality credentials such as ISO 9001, signals a patient-centric strategy to scale AI-powered digital solutions and expand global access and health outcomes for people living with diabetes and related chronic diseases

Sinocare Inc. (300298.SZ) - Intro

• Global reach: products available in 135 countries with a particularly strong presence in emerging markets across Asia, Africa and Latin America.
• R&D commitment: over ¥200 million CNY invested in research and development in 2021, reflecting ongoing focus on innovation in biosensing, algorithms and telehealth integration.
• Quality and compliance: ISO 9001 certified, with multiple product registrations and regulatory clearances across target markets.

• Patient-centric care: prioritize accurate, accessible diagnostics and continuous-management tools that empower people with diabetes and chronic conditions to improve outcomes.
• Technology-driven access: scale affordable digital solutions that integrate devices, cloud analytics and clinician workflows to broaden care delivery.

• To be a global leader enabling proactive chronic disease management through intelligent, connected diagnostics-reducing complications and healthcare costs worldwide.

• Leadership: drive innovation in device accuracy, usability and data-driven care pathways.
• Integrity: uphold regulatory compliance, data privacy and transparent reporting.
• Collaboration: partner with healthcare systems, payers and tech firms to extend reach and interoperability.
• Quality: maintain international manufacturing and quality standards, exemplified by ISO 9001 certification.
• Accessibility: commit to cost-effective products and programs targeting under-served populations in emerging markets.

Sinocare Inc. (300298.SZ) - Overview

• Mission emphasis: accessible, empathetic care - "guided by love" signals a patient-first, service-oriented culture.
• Target population: people living with diabetes and related chronic diseases - enabling targeted product design and disease-management services.
• Strategic focus: innovation and quality - continuous investment in R&D and device accuracy to improve clinical outcomes.
• Global access: expansion into overseas markets and distribution partnerships to broaden patient reach and affordability.

• Device accuracy and quality: continuous improvement programs and EN ISO/FDA/CE certifications for multiple products to meet clinical standards.
• Affordability & access: tiered pricing, public-health partnerships, and distribution networks that increased international revenue share to ~18% in 2023.
• Patient outcomes focus: clinical validation studies and post-market surveillance to track glycemic control improvements among users.
• R&D intensity: R&D spend rose to ~5.9% of revenue in 2023 (RMB 120 million) reflecting commitment to novel sensors, algorithms and integrated care tools.

• Vision: to be a global leader in diabetes and chronic disease management solutions - combining devices, data and services to improve long-term health outcomes.
• Strategic pillars: product innovation (BGM, CGM, test strips, management platforms), channel diversification (hospital, community, retail, e-commerce), and international expansion.
• Investment priorities: scale manufacturing capacity, expand clinical evidence base, and integrate digital care pathways to boost recurring revenue from services and consumables.

• Compassion: patient-support programs, educational outreach, and design choices that prioritize usability for elderly and multi-morbidity patients.
• Quality: adherence to strict quality controls, third-party certifications, and sustained gross margins above 58% in recent years.
• Innovation: steady growth in R&D headcount and budget to deliver next-generation monitoring and remote care solutions.
• Accessibility: pricing strategies, supply-chain initiatives, and partnerships to broaden access across urban and rural markets.

Sinocare Inc. (300298.SZ) - Mission Statement

• Lead in digital transformation of diabetes care by embedding connectivity, data science, and clinical decision support into device ecosystems.
• Set industry standards for device accuracy, interoperability, and patient-centered digital workflows.
• Scale internationally to serve diverse populations and healthcare systems while adapting solutions to local clinical and regulatory environments.
• Drive innovation through partnerships, AI-enabled product development, and evidence generation to demonstrate improved outcomes and cost-effectiveness.

• Product integration: bringing glucose meters, continuous monitoring adjuncts, and related assays into cloud-native care platforms.
• AI and data analytics: deploying predictive models for risk stratification, adherence monitoring, and therapy optimization.
• Global expansion: building distribution, clinical partnerships, and regulatory footprints across emerging and developed markets.
• Evidence & reimbursement: generating real-world data and health-economic evidence to support payer adoption.

• Device accuracy and regulatory compliance: prioritizing clinical-grade performance to enable clinical adoption and reimbursement.
• Platform-first development: ensuring devices are cloud-ready and API-accessible for integration with hospital EMRs and telehealth platforms.
• Partnerships: collaborating with payers, hospitals, diabetes clinics, and tech firms to scale care pathways that incorporate Sinocare devices and services.
• Local adaptation: tailoring pricing, service models, and regulatory filings to accelerate uptake in target international markets.

• Clinical outcomes: reduction in average HbA1c among engaged users, fewer hypoglycemia events
• Engagement metrics: daily active users, adherence to testing schedules, retention in digital programs
• Commercial metrics: revenue growth in digital/recurring-service lines, international sales share
• Innovation metrics: number of AI models deployed, regulatory clearances for digital medical devices

Sinocare Inc. (300298.SZ) - Vision Statement

• Customer-centered innovation: develop high-quality, easy-to-use products that enable healthier lives for people with diabetes and other chronic conditions.
• Employee care and growth: provide a supportive environment that values individuals, encourages continuous learning, and rewards contribution.
• Partner respect and collaboration: work ethically and transparently with distributors, hospitals, research institutions, and suppliers.
• Societal responsibility: pursue sustainable practices, public health initiatives, and community programs that reduce disease burden.
• Shareholder stewardship: balance long-term value creation with rigorous governance and financial discipline.

• Customer initiatives: subsidized screening programs, simplified user interfaces, and affordability tiers for test strips and devices.
• Employee programs: internal training academies, performance-linked incentives, and health/wellness benefits.
• Partner and community actions: joint pilot projects with hospitals, public screening campaigns, and supplier audits enforcing ethical standards.